webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Mal-PEG2-VCP-NB

  CAS No.: 2395887-69-9   Cat No.: BADC-01106   Purity: >95.0% 4.5  

Mal-PEG2-VCP-NB is a maleimide-activated ADC linker with valine-citrulline protease-cleavable sequence and nitrobenzyl group, designed for targeted intracellular drug release in antibody-drug conjugates.

Mal-PEG2-VCP-NB

Structure of 2395887-69-9

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C36H45N7O13
Molecular Weight
783.78
Shipping
Room temperature, or blue ice upon request.
Shipping
Store at -20 °C, keep in dry and avoid sunlight.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[3-[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxy]propanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate
IUPAC Name
[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[3-[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxy]propanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate
Canonical SMILES
CC(C)C(C(=O)NC(CCCNC(=O)N)C(=O)NC1=CC=C(C=C1)COC(=O)OC2=CC=C(C=C2)[N+](=O)[O-])NC(=O)CCOCCOCCN3C(=O)C=CC3=O
InChI
InChI=1S/C36H45N7O13/c1-23(2)32(41-29(44)15-18-53-20-21-54-19-17-42-30(45)13-14-31(42)46)34(48)40-28(4-3-16-38-35(37)49)33(47)39-25-7-5-24(6-8-25)22-55-36(50)56-27-11-9-26(10-12-27)43(51)52/h5-14,23,28,32H,3-4,15-22H2,1-2H3,(H,39,47)(H,40,48)(H,41,44)(H3,37,38,49)/t28-,32-/m0/s1
InChIKey
UTNZOKGPGOHCAG-IUDBTDONSA-N
Solubility
10 mm in DMSO
Appearance
Solid
Shelf Life
0-4°C for short term (days to weeks), or -20°C for long term (months).
Shipping
Room temperature, or blue ice upon request.
Storage
Store at -20 °C, keep in dry and avoid sunlight.
Form
Solid
Biological Activity
Mal-PEG2-VCP-NB is a nonclaevable ADC linker containing a Maleimide group, 2-unit PEG and a VCP NB.

Mal-PEG2-VCP-NB is a specialized bioconjugate that combines the maleimide (Mal) group, a polyethylene glycol (PEG2) spacer, a VCP (Valine-Citrulline-PAB) linker, and nitrobenzyl (NB) groups. This compound is primarily used in targeted drug delivery and cancer therapy. The maleimide group reacts efficiently with thiol groups on biomolecules like antibodies or peptides, enabling stable conjugation. The PEG2 spacer improves solubility, reduces immunogenicity, and enhances the pharmacokinetics of the conjugate, ensuring it remains in circulation longer. The VCP linker can be cleaved in the tumor microenvironment, facilitating controlled drug release. The NB group can undergo photochemical activation, allowing for targeted therapy activation via light exposure, making it a versatile tool in photodynamic therapy.

One of the primary applications of Mal-PEG2-VCP-NB is in the development of antibody-drug conjugates (ADCs) for cancer treatment. By attaching cytotoxic drugs or other therapeutic agents to antibodies through the VCP linker, the drug is delivered specifically to tumor cells expressing target antigens. The maleimide group enables efficient conjugation to the antibody’s thiol groups, while the PEG2 spacer enhances the solubility and circulation time, ensuring that the conjugate reaches the tumor site. The NB moiety adds an additional layer of precision by enabling light-induced activation of the drug in the tumor microenvironment, thereby improving the selectivity and effectiveness of treatment while minimizing damage to surrounding healthy tissue. This approach can be highly effective in cancers that are difficult to treat with conventional therapies.

Mal-PEG2-VCP-NB also shows promise in the development of photochemically activated therapies. The nitrobenzyl (NB) group within the conjugate can undergo photochemical activation when exposed to specific wavelengths of light. This property makes Mal-PEG2-VCP-NB ideal for use in photodynamic therapy (PDT) or photochemical internalization (PCI), where light is used to activate the drug selectively at the tumor site. This type of activation minimizes the risk of systemic toxicity, as the therapeutic agent remains inert until targeted by light. Photodynamic therapy is particularly beneficial in treating localized tumors and for therapies requiring minimal invasiveness, offering an innovative alternative to traditional methods like chemotherapy or radiation therapy.

Another important application of Mal-PEG2-VCP-NB is in the development of targeted diagnostic imaging agents. The conjugate can be used to label imaging probes, such as fluorescent dyes or radiolabeled compounds, which can be directed to specific cells or tissues of interest. The PEG2 spacer ensures the conjugate remains soluble and stable in vivo, while the VCP linker provides a mechanism for controlled release of the imaging agent. The NB group can be leveraged for specific activation in imaging techniques like fluorescence imaging or positron emission tomography (PET). This allows for precise tumor detection, localization, and monitoring of therapeutic efficacy in real time, aiding in personalized treatment planning and improving clinical outcomes.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: XMT-1519 conjugate-1 | NH-bis(C1-Boc) | H-D-trans-Hyp-OMe HCl | Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br | Fluorescein-DBCO | Boc-D-trans-Hyp-OH | DBCO-PEG3-oxyamine | Me-Tet-PEG5-NHS | Me-Tet-PEG9-COOH | Me-Tet-PEG5-COOH | Mal-PEG2-VCP-NB
Send Inquiry
Verification code
Inquiry Basket